Skip to content
Open access · CC-BY via OpenAlex

Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance

Nina Rembiałkowska, Zofia Kocik, Amelia Kłosińska, Maja Kübler, Agata Pałkiewicz, Weronika Rozmus, Mikołaj Sędzik, Helena Wojciechowska, Agnieszka Gajewska-Naryniecka

Pharmaceuticals · 2025 · ▲ 45 citations

Abstract

Chronic inflammation, while originally a protective physiological response, is increasingly recognized as a key contributor to carcinogenesis. Prolonged inflammatory signaling leads to the sustained production of reactive oxygen and nitrogen species (ROS/RNS), resulting in direct and indirect DNA damage, including base modifications, strand breaks, and DNA cross-linking. Simultaneously, pro-inflammatory mediators such as NF-κB, IL-6, and TNF-α can interfere with DNA repair mechanisms, altering the efficiency of key pathways such as base excision and mismatch repair. Immune cells infiltrating chronically inflamed tissues, including macrophages and neutrophils, further exacerbate genomic instability through ROS/RNS release and cytokine production, creating a tumor-promoting microenvironment. Additionally, chronic inflammation has been implicated in the development of resistance to chemotherapy and radiotherapy by modulating DNA damage response pathways. Understanding the interplay between inflammation, genomic instability, and therapy resistance provides a framework for novel treatment strategies. Targeting chronic inflammation with non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or biological agents such as monoclonal antibodies offers promising avenues for cancer prevention and treatment. Targeting inflammation with NSAIDs, corticosteroids, and monoclonal antibodies shows promise in cancer prevention and therapy, particularly in lung and pancreatic cancer. These agents act by blocking key inflammatory pathways like COX-2, NF-κB, and cytokine signaling. However, potential adverse effects require further clinical evaluation.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3390/ph18091406
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Rembiałkowska, N., Kocik, Z., Kłosińska, A., Kübler, M., Pałkiewicz, A., Rozmus, W., Sędzik, M., Wojciechowska, H., &amp; Gajewska-Naryniecka, A. (2025). Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance. <em>Pharmaceuticals</em>. https://doi.org/10.3390/ph18091406
Vancouver
Rembiałkowska N, Kocik Z, Kłosińska A, Kübler M, Pałkiewicz A, Rozmus W, et al. Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance. Pharmaceuticals. 2025. doi:10.3390/ph18091406.
BibTeX
@article{nina2025Inflam, title = {Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance}, author = {Nina Rembiałkowska and Zofia Kocik and Amelia Kłosińska and Maja Kübler and Agata Pałkiewicz and Weronika Rozmus and Mikołaj Sędzik and Helena Wojciechowska and Agnieszka Gajewska-Naryniecka}, journal = {Pharmaceuticals}, year = {2025}, doi = {10.3390/ph18091406}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings